10-Q · May 12, 2026
USANA Health Sciences reported a Q1 2026 performance that showed a modest increase in consolidated net sales of 0.3% to $250.2 million compared to prior year, driven by a significant 740.7% revenue growth in the Rise…
Earnings analysis · 10-Q
USNA earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
USANA reported a weak Q2, with revenue of $223.273 million declining both sequentially and year over year and GAAP diluted EPS of $(1.16), including a $29.137 million Hiya goodwill impairment. Management reduced FY2026…
Read full summary
USANA reported a weak Q2, with revenue of $223.273 million declining both sequentially and year over year and GAAP diluted EPS of $(1.16), including a $29.137 million Hiya goodwill impairment. Management reduced FY2026 sales outlook to $910 million and now expects a GAAP diluted loss of $(0.61), while adjusted EPS outlook declined to $0.76. The filing states that risk factors have not changed materially from the 2025 Form 10-K, but the earnings miss, impairment, and substantially lower outlook remain significant negatives.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.16
What stood out
-
Revenue declined sequentially and year over year
Q2 revenue was $223.273 million, down from $250 million in Q1 2026 and $236 million in Q2 2025, representing sequential and year-over-year declines of approximately 10.7% and 5.4%, respectively.
-
GAAP EPS swung to a loss
GAAP diluted EPS was a loss of $1.16 versus earnings of $0.41 in Q1 2026 and $0.52 in Q2 2025. The quarter included a preliminary $29.137 million goodwill impairment related to Hiya.
-
FY2026 outlook was reduced
The company lowered FY2026 net-sales outlook to $910 million from the prior range of $925 million-$1.0 billion, and lowered GAAP diluted EPS outlook to $(0.61) from $1.11-$1.45.
-
Repurchases remained suspended
No common stock was repurchased during the three months ended July 4, 2026, while $34.0 million remained authorized under the repurchase plan at quarter-end.
-
No material control deficiencies reported
Management concluded disclosure controls were effective as of July 4, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
What to watch
-
Hiya impairment highlights asset risk
The $29.137 million preliminary Hiya goodwill impairment signals deterioration in the acquired business and contributed to a GAAP diluted loss of $1.16 for Q2.
-
Revenue missed consensus
Q2 revenue of $223.273 million was below the $235.002 million consensus estimate by $11.729 million, indicating continued demand or execution pressure.
-
Earnings outlook deteriorated sharply
The FY2026 GAAP diluted EPS outlook was reduced to a loss of $(0.61) from prior guidance of $1.11-$1.45, while adjusted EPS outlook fell to $0.76 from $1.95-$2.29.
Management's outlook
FY2026 consolidated net-sales outlook was lowered to $910 million from $925 million-$1.0 billion. GAAP diluted EPS outlook was lowered to $(0.61) from $1.11-$1.45; adjusted diluted EPS outlook is $0.76, down from $1.95-$2.29.
Earlier filings 4
10-K · March 16, 2026
USANA reported $925.0 million of net sales for fiscal 2025 while executing an omni-channel strategy that integrates its core direct-selling business with recent acquisitions Hiya and Rise. The company highlights product…
10-Q · August 5, 2025
USANA reported consolidated Q2 net sales of $235.8 million, up 10.8% year-over-year driven primarily by Hiya (Q2 Hiya sales $33.931 million) while the core direct selling business declined. Gross margin compressed to…
10-K · March 12, 2025
USANA reported 2024 net sales of $855 million and finished the year with approximately 454,000 direct selling active Customers. The company is executing an "Associate-first" strategy with continued focus on China…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.